Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.
Su YJ, Kramer AM, Hamilton MP, Agarwal N, Srinagesh HK, Baird JH, Sahaf B, Kuo A, Ehlinger ZJ, Desai MH, Rietberg SP, Tunuguntla R, Patel S, Chinnasamy H, Gkitsas-Long N, Klysz DD, Brown AK, Bharadwaj S, Dahiya S, Smith M, Muffly L, Mackall CL, Good Z, Feldman SA, Miklos DB, Frank MJ. Su YJ, et al. Among authors: muffly l. Cancer Discov. 2025 Jan 7. doi: 10.1158/2159-8290.CD-24-1071. Online ahead of print. Cancer Discov. 2025. PMID: 39775812
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: muffly l. Blood. 2025 Jan 7:blood.2024025154. doi: 10.1182/blood.2024025154. Online ahead of print. Blood. 2025. PMID: 39775763
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Roloff GW, et al. Among authors: muffly l. J Clin Oncol. 2024 Oct 17:JCO2400321. doi: 10.1200/JCO.24.00321. Online ahead of print. J Clin Oncol. 2024. PMID: 39418622
The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL.
Othman T, Logan AC, Muffly L, Leonard J, Park J, Shah B, Aldoss I. Othman T, et al. Among authors: muffly l. J Natl Compr Canc Netw. 2024 Oct;22(8):e247065. doi: 10.6004/jnccn.2024.7065. J Natl Compr Canc Netw. 2024. PMID: 39413830 Review.
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
Sidana S, Bankova AK, Hosoya H, Kumar SK, Holmes TH, Tamaresis J, Le A, Muffly LS, Maysel-Auslender S, Johnston L, Arai S, Lowsky R, Meyer E, Rezvani A, Weng WK, Frank MJ, Shiraz P, Maecker HT, Lu Y, Miklos DB, Shizuru JA. Sidana S, et al. Among authors: muffly ls. Blood Cancer J. 2024 Oct 9;14(1):173. doi: 10.1038/s41408-024-01152-1. Blood Cancer J. 2024. PMID: 39384609 Free PMC article. Clinical Trial.
Utilization of allogeneic hematopoietic stem cell transplantation among patients with newly diagnosed acute myeloid leukemia in California: a population-based linked dataset study.
Meyer CL, Keegan THM, Brunson A, Auletta JJ, Morton LM, Wun T, Schonfeld SJ, Valcarcel B, Abrahão R, Yusuf RA, Muffly L. Meyer CL, et al. Among authors: muffly l. Haematologica. 2024 Aug 29. doi: 10.3324/haematol.2024.285648. Online ahead of print. Haematologica. 2024. PMID: 39219504 Free article.
Predicting relapse in acute lymphoblastic leukemia.
Schwartz MS, Muffly LS. Schwartz MS, et al. Among authors: muffly ls. Leuk Lymphoma. 2024 Dec;65(13):1934-1940. doi: 10.1080/10428194.2024.2387728. Epub 2024 Aug 31. Leuk Lymphoma. 2024. PMID: 39216505 Free article. Review.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Aldoss I, et al. Among authors: muffly ls. Blood Adv. 2024 Dec 10;8(23):6139-6147. doi: 10.1182/bloodadvances.2024013747. Blood Adv. 2024. PMID: 39093952 Free PMC article.
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Frank MJ, Baird JH, Kramer AM, Srinagesh HK, Patel S, Brown AK, Oak JS, Younes SF, Natkunam Y, Hamilton MP, Su YJ, Agarwal N, Chinnasamy H, Egeler E, Mavroukakis S, Feldman SA, Sahaf B, Mackall CL, Muffly L, Miklos DB; CARdinal-22 Investigator group. Frank MJ, et al. Among authors: muffly l. Lancet. 2024 Jul 27;404(10450):353-363. doi: 10.1016/S0140-6736(24)00746-3. Epub 2024 Jul 9. Lancet. 2024. PMID: 38996463 Free article. Clinical Trial.
127 results